Lorenzo Ferrando

17PUBLICATIONS
61CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jan 03, 2023
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

Lorenzo Ferrando, Andrea Vingiani, Anna Garuti

|Dec 23, 2022
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma.

Lorenza Pastorino, Bruna Dalmasso, Eleonora Allavena

|Feb 24, 2022
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.

Gabriella Cirmena, Lorenzo Ferrando, Francesco Ravera

|Sep 18, 2021
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies.

Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu

|Jul 20, 2021
Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.

Martina Dameri, Lorenzo Ferrando, Gabriella Cirmena

|Apr 17, 2021
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.

Edaise M da Silva, Pier Selenica, Mahsa Vahdatinia

Pageof 3

Frequent Collaborators

8 joint publications

Jorge S Reis-Filho

4 joint publications

Gabriele Zoppoli

4 joint publications

Edaise M da Silva

4 joint publications

Fresia Pareja